Literature DB >> 34647231

Revisit PEG-Induced Precipitation Assay for Protein Solubility Assessment of Monoclonal Antibody Formulations.

Martha J Scannell1, Matthew W Hyatt2, Ivan L Budyak2, Mahlet A Woldeyes3, Ying Wang4.   

Abstract

PURPOSE: Protein solubility is an important attribute of pharmaceutical monoclonal antibody (MAb) formulations, particularly at high MAb concentrations. PEG-induced protein precipitation has been routinely used to assess protein solubility. To provide insights for better understanding and implementation of PEG-induced protein precipitation assay, this work compares different solubility measures and examines their relevance to loss of protein solubility in concentrated formulations.
METHODS: Solubility of a MAb in 15 formulations was evaluated using PEG-induced precipitation assay. Three apparent protein solubility measures, the middle-point and onset PEG concentrations (cmid and conset) as well as the binding free energy (μB), were obtained from the PEG-induced protein precipitation assay and compared to the DLS protein interaction parameter (kD). Visual inspection of loss of protein solubility in concentrated formulations during storage was used to further examine the discrepancy of protein solubility ranking by these measures.
RESULTS: PEG-induced precipitation assay predicted overall protein solubility ranking similar to that by DLS kD. However, for three formulations with ionic excipients NaCl, Arg·Cl, and Arg·Glu·Cl, PEG-induced precipitation assay yielded more accurate predictions compared to DLS kD measurements. Furthermore, μB showed superior ability in distinguishing protein solubility for these formulations.
CONCLUSIONS: This study demonstrated good correlations between the protein solubility measures obtained from PEG-induced precipitation experiments and DLS kD measurement. It also provides one example in which protein solubility ranking by binding free energy is more accurate than the other measures. The results support the theoretical proposition that μB has a potential to serve as standard protein solubility measure.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Concentrated formulation; Liquid–liquid phase separation (LLPS); Monoclonal antibody (MAb); PEG-induced precipitation; Protein solubility

Mesh:

Substances:

Year:  2021        PMID: 34647231     DOI: 10.1007/s11095-021-03119-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

Review 1.  Immunogenicity of Therapeutic Protein Aggregates.

Authors:  Ehab M Moussa; Jainik P Panchal; Balakrishnan S Moorthy; Janice S Blum; Marisa K Joubert; Linda O Narhi; Elizabeth M Topp
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

2.  Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.

Authors:  Todd J Gibson; Katie Mccarty; Iain J Mcfadyen; Ethan Cash; Paul Dalmonte; Kenneth D Hinds; Adam A Dinerman; Juan C Alvarez; David B Volkin
Journal:  J Pharm Sci       Date:  2010-10-25       Impact factor: 3.534

Review 3.  The therapeutic monoclonal antibody market.

Authors:  Dawn M Ecker; Susan Dana Jones; Howard L Levine
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 4.  Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.

Authors:  Lora Hamuro; Grzegorz Kijanka; Francis Kinderman; Harald Kropshofer; De-Xiu Bu; Monica Zepeda; Vibha Jawa
Journal:  J Pharm Sci       Date:  2017-05-31       Impact factor: 3.534

Review 5.  Protein aggregation - Mechanisms, detection, and control.

Authors:  Wei Wang; Christopher J Roberts
Journal:  Int J Pharm       Date:  2018-08-23       Impact factor: 5.875

6.  Quantitative evaluation of colloidal stability of antibody solutions using PEG-induced liquid-liquid phase separation.

Authors:  Ying Wang; Ramil F Latypov; Aleksey Lomakin; Julie A Meyer; Bruce A Kerwin; Suresh Vunnum; George B Benedek
Journal:  Mol Pharm       Date:  2014-04-15       Impact factor: 4.939

7.  Development of a high-throughput solubility screening assay for use in antibody discovery.

Authors:  Qing Chai; James Shih; Caroline Weldon; Samantha Phan; Bryan E Jones
Journal:  MAbs       Date:  2019-03-26       Impact factor: 5.857

8.  A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development.

Authors:  Vishal M Toprani; Sangeeta B Joshi; Lisa A Kueltzo; Richard M Schwartz; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2016-06-29       Impact factor: 3.534

Review 9.  Test models for the evaluation of immunogenicity of protein aggregates.

Authors:  Teresa Kraus; Gerhard Winter; Julia Engert
Journal:  Int J Pharm       Date:  2019-01-18       Impact factor: 5.875

10.  The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.

Authors:  Liusong Yin; Xiaoying Chen; Abhinav Tiwari; Paolo Vicini; Timothy P Hickling
Journal:  J Immunol Res       Date:  2015-11-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.